VERBIO Vereinigte BioEnergie AG

Reported Q3 group EBITDA was EUR 60.2 million, up from EUR 8.2 million in Q3 last year and EUR 30.1 million in the previous quarter. In the first 9 months, operating cash flow was EUR 96.4 million, capital expenditures on PPE were EUR 63.4 million, free cash flow was EUR 33 million, net debt fell to EUR 126.8 million, and the equity ratio improved to 59.3%. On volume, biodiesel output was 458,000 tonnes in the first 9 months, ethanol production was 431,000 tonnes, and biomethane production exceeded 1 terawatt hour for the first time after 9 months. Segment-wise, Q3 biodiesel revenue was EUR 203 million with EBITDA of EUR 18.5 million, and bioethanol/biomethane EBITDA was EUR 34.2 million. Management reiterated full-year EBITDA guidance of EUR 100 million to EUR 140 million and said it now expects results at the upper end of that range, while net financial debt is now expected to be less than EUR 140 million at year-end.

Olaf Troeber framed the quarter as a strong execution story backed by better market conditions, improved regulation, and geopolitical factors. He emphasized that RED III and the U.S. RVOs are improving market quality and visibility, while the company is benefiting from optimization, product mix, and higher asset utilization rather than just more volume. His tone was confident but disciplined: he repeatedly noted that Verbio is close to the top end of guidance, but not yet prepared to raise it further.

Olaf Troeber highlighted that the stronger EBITDA came mainly from higher gross margin, with lower operating costs, higher operating income, and gains from commodity forward transactions also helping. He pointed to operating cash flow of EUR 96.4 million after 9 months, PPE investments of EUR 63.4 million, positive free cash flow of EUR 33 million, and net debt of EUR 126.8 million, saying leverage is on track to fall below 1x net debt-to-EBITDA. He also said the equity ratio improved to 59.3% despite quasi-equity investment grants being recognized as liabilities.

Analysts focused on how much more upside remains in guidance, the sensitivity to GHG quota prices, and whether current high biofuel prices could lead to demand destruction. Management said a EUR 100 increase in the GHG quota price can add EUR 40 million to EUR 80 million to annual EBITDA, depending on optimization and feedstock mix, but declined to raise guidance yet, saying it is still mid-May and that an ad hoc would be required if full-year EBITDA looks set to exceed EUR 140 million. They also said Q4 EBITDA should not match Q3 because Q3 benefited from strong seasonal quota demand, that the temporary biological issue in Germany was resolved mid-April, and that Canadian utilization in Q4 should be close to 100%.